Aromatase inhibitors: From bench to bedside and back

Breast Cancer

Volumn 15, Issue 1, 2008, Pages 17-26

  Geisler, Jürgen ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

Anastrozole; Aromatase; Exemestane; Letrozole; Translational research

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR;

ANIMAL; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CLINICAL TRIAL; DRUG RESISTANCE; FEMALE; HISTORY; HUMAN; OVARIECTOMY; PATHOPHYSIOLOGY; PHYSIOLOGY; TECHNOLOGY;

ANIMALS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; HISTORY, 20TH CENTURY; HUMANS; MODELS, ANIMAL; OVARIECTOMY; TECHNOLOGY TRANSFER;

EID: 43149106508     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-007-0002-3     Document Type: Conference Paper

References (100)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma. Suggestions for a new method of treatment with illustrative cases. Lancet. 1896;2:104-7.
2. Dao TL, Huggins C. Bilateral adrenalectomy in the treatment of cancer of the breast. Arch Surg. 1955;71:645-7.
3. Huggins C, Dao TL-Y. Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast. JAMA. 1953;151:1388-94.
4. Newsome HH, Brown PW, Terz JJ, Lawrence W Jr. Medical and surgical adrenalectomy in patients with advanced breast carcinoma. Cancer. 1977;39:542-6. (Pubitemid 8063516)
5. Pearson OH. Hypophysectomy in the treatment of metastatic mammary cancer. CA Cancer J Clin. 1959;9:159-62.
6. Nosaquo ND. Androgens and estrogens in the treatment of disseminated mammary carcinoma. JAMA. 1960;172:135-47.
7. Kennedy BJ. Massive estrogen administration in premenopausal women with metastatic breast cancer. Cancer. 1962;15:641-8.
8. Lonning PE, Taylor PD, Anker G, et al. High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat. 2001;67:111-6. (Pubitemid 32744491)
9. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell. 2004;5:207-13. (Pubitemid 38402112)
10. Santen RJ, Santner S, Davis B, Veldhuis J, Samojlik E, Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab. 1978;47:1257-65. (Pubitemid 9091287)
11. Lonning PE, Kvinnsland S. Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. Drugs. 1988;35:685-10.
12. Steinach E, Kun H. Transformation of male sex hormones into a substance with action of a female hormone. Lancet. 1937;2:845.
13. Nathanson IT, Towne LE. The urinary excretion of estrogens, androgens and FSH following administration of testosterone to human female castrates. Endocrinology. 1939;25:754-8.
14. West CD, Damast BL, Sarro SD, Pearson OH. Conversion of testosterone to estrogens in castrated, adrenalectomized human females. J Biol Chem. 1956;218:409-18.
15. Ryan KJ. Biological aromatization of steroids. J Biol Chem. 1959;234:268-72.
16. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab. 1973;36:207-14.
17. Miller WR, Forrest AP. Oestradiol synthesis by a human breast carcinoma. Lancet. 1974;2:866-8.
18. Geisler J, Lonning PE. Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005; 11:2809-21. (Pubitemid 40525179)
19. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer. 1996;74:1286-91. (Pubitemid 26360121)
20. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res. 1998;4:2089-93. (Pubitemid 28415652)
21. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002;20:751-7. (Pubitemid 34111382)
22. Dowsett M, Jones A, Johnston SR, Jacobs S, Trunet P, Smith IE. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res. 1995;1:1511-5. (Pubitemid 26028086)
23. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001;92:2247-58.
24. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19:2596-606. (Pubitemid 32451796)
25. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol. 2003;14:1391-8. (Pubitemid 37185285)
26. Baum M, Buzdar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359:2131-9. (Pubitemid 34694019)
27. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350:1081-92. (Pubitemid 38298988)
28. Goss PE, Ingle JN, Martino S, et al. Arandomized trial of letrozole in postmenopausal women after five years of tamoxifen for earlystage breast cancer. N Engl J Med. 2003;349:1793-1802. (Pubitemid 37362955)
29. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747-57. (Pubitemid 43016814)
30. Purba HS, Bhatnagar A. A comparison of methods measuring aromatase activity in human placenta and rat ovary. J Enzyme Inhib. 1990;4:169-178.
31. Brodie A, Lu Q, Liu Y, Long B. Aromatase inhibitors and their antitumor effects in model systems. End Rel Cancer. 1999;6:205-10. (Pubitemid 29260053)
32. Miller WR, Dixon JM. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer. 2000;Supplement: S9-14.
33. Batzl-Hartmann C, Evans DB, Bhatnagar A. Comparative aromatase enzyme kinetic studies on fadrozole, formestane, letrozole, anastrozole and exemestane, San Antonio Breast Cancer Conference, San Antonio, TX, USA, 2003.
34. Lonning PE, Jacobs S, Jones A, Haynes B, Powles T, Dowsett M. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer. 1991;63:789-93.
35. Brodie A, Lu Q, Liu Y, Long B, Wang JP, Yue W. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Oncology (Huntingt). 1998;12:36-40.
36. Brodie AH, Mouridsen HT. Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy. Am J Clin Oncol. 2003;26:S17-26. (Pubitemid 36966419)
37. Brodie A, Lu Q, Yue W, Wang J, Liu Y. Intratumoral aromatase model: the effects of letrozole (CGS 20267). Breast Cancer Res Treat. 1998;49(Suppl 1):S23-6; discussion S33-7.
38. Fisher CR, Gracves KH, Parlow AF, Simpson ER. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the CYP19 gene. Proc Natl Acad Sci USA. 1998;95:6965-70. (Pubitemid 28278090)
39. Jacobs S, Lønning PE, Haynes B, Griggs L, Dowsett M. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J Enzyme Inhib. 1991;4:315-25.
40. MacNeill FA, Jones AL, Jacobs S, Lonning PE, Powles TJ, Dowsett M. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer. 1992;66:692-7.
41. MacNeill FA, Jacobs S, Dowsett M, Lonning PE, Powles TJ. The effects of oral 4-hydroxyandrostenedione on peripheral aromatization in post-menopausal breast cancer patients. Cancer Chemother Pharmacol. 1995;36:249-54.
42. Jones AL, MacNeill F, Jacobs S, Lonning PE, Dowsett M, Powles TJ. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer. 1992;28A:1712-6.
43. MacNeill FA, Jacobs S, Lonning PE, Powles TJ, Dowsett M. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression. Br J Cancer. 1994;69:1171-5. (Pubitemid 24161882)
44. Dowsett M, Howell R, Salter J, Thomas NM, Thomas EJ. Effects of the pure anti-oestrogen ICI 182780 on oestrogen receptors, progesterone receptors and Ki67 antigen in human endometrium in vivo. Hum Reprod. 1995;10:262-7.
45. Geisler J, Lonning PE. Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations. J Steroid Biochem Mol Biol. 2005;95:75-81. (Pubitemid 41148977)
46. Barone RM, Shamonki IM, Siiteri PK, Judd HL. Inhibition of peripheral aromatization of androstenedione to estrone in postmenopausal women with breast cancer using D1-testoloclactone. J Clin Endocrinol Metab. 1979;49:672-6. (Pubitemid 10198297)
47. Geisler J, Lundgren S, Berntsen H, Greaves JL, Lonning PE. Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients. J Clin Endocrinol Metab. 1998;83:2687-93. (Pubitemid 28493761)
48. Dowsett M, MacNeill F, Mehta A, et al. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6- dione ('pyridoglutethimide') in postmenopausal breast cancer patients. Br J Cancer. 1991; 64:887-94.
49. Klepp R, Lonning PE, Kvinnsland S. Plasma estrone and estrone sulphate in breast cancer patients treated with the aromatase inhibitor CGS 16949A. Acta Oncol. 1990;29:469-71. (Pubitemid 20262592)
50. Johannessen DC, Adlercreutz H, Fotsis T, Lonning PE. Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione. Br J Cancer. 1993; 68:393-8. (Pubitemid 23229444)
51. Johnston SR, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res. 1994;54:5875-81. (Pubitemid 24375222)
52. Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Mol Biol. 2003;86:245-53. (Pubitemid 37420000)
53. Miller WR, Telford J, Love CD, et al. Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast. Breast. 1998;7:273-6. (Pubitemid 28510739)
54. Reed MJ, Aherne GW, Ghilchik MW, Patel S, Chakraborty J. Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues. Int J Cancer. 1991;49: 562-5.
55. de Jong PC, van de Ven J, Nortier HW, et al. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Res. 1997;57:2109-11. (Pubitemid 27247021)
56. Geisler J, Detre S, Berntsen H, et al. Influence of neoadjuvant anastrozole (arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res. 2001;7:1230-6. (Pubitemid 32708674)
57. Geisler J, Ekse D, Helle H, Lønning PE. Letrozole suppresses tissue and plasma estradiol, estrone and estrone sulfate more effectively compared to anastrozole. Breast Cancer Res Treat. 2006;100:S23-4.
58. Geisler J, Berntsen H, Lonning PE. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. J Steroid Biochem Mol Biol. 2000;72:259-64. (Pubitemid 30261530)
59. Janicke F, Pronzato P. What is the optimal strategy for postoperative treatment with aromatase inhibitors in the adjuvant setting?. Best Pract Res Clin Endocrinol Metab. 2006;20(Suppl 1):S31-45. (Pubitemid 44873764)
60. Mauriac L. Aromatase inhibitors: effective endocrine therapy in the early adjuvant setting for postmenopausal women with hormone-responsive breast cancer. Best Pract Res Clin Endocrinol Metab. 2006;20(Suppl 1):S15-29. (Pubitemid 44873765)
61. Mouridsen HT, Robert NJ. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer. MedGenMed. 2005;7:20.
62. Luftner D, Henschke P, Pollmann D, Schildhauer S, Possinger K. Prescription pattern of aromatase inhibitors in the adjuvant setting in Germany-final results of a survey among german breast cancer specialists. Onkologie. 2005;28:639-44. (Pubitemid 41759066)
63. Spano JP, Khayat D, Delozier T. [Aromatase inhibitors in adjuvant setting in breast cancer]. Bull Cancer. 2004;91(Suppl 4):S239-43. (Pubitemid 40115468)
64. Clemons M, Coleman RE, Verma S. Aromatase inhibitors in the adjuvant setting: bringing the gold to a standard?. Cancer Treat Rev. 2004;30:325-32. (Pubitemid 38735701)
65. Goss PE. Emerging role of aromatase inhibitors in the adjuvant setting. Am J Clin Oncol. 2003;26:S27-33. (Pubitemid 36966420)
66. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003;21:2597-9. (Pubitemid 46606343)
67. Buzdar AU. New generation aromatase inhibitors-from the advanced to the adjuvant setting. Breast Cancer Res Treat. 2002;75(Suppl 1):S13-7; discussion S33-5. (Pubitemid 35015084)
68. Coombes RC. Aromatase inhibitors and their use in the adjuvant setting. Recent Results Cancer Res. 1998;152:277-84.
69. Dowsett M. Endocrine resistance in advanced breast cancer. Acta Oncol. 1996;35(Suppl 5):91-5.
70. Jordan VC. Targeting antihormone resistance in breast cancer: a simple solution. Ann Oncol. 2003;14:969-70. (Pubitemid 36950157)
71. Lonning PE. Cross-resistance to different aromatase inhibitors in breast cancer treatment. Endocr Relat Cancer. 1999;6:251-7. (Pubitemid 29260060)
72. Schiff R, Massarweh S, Shou J, Osborne CK. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin Cancer Res. 2003;9:447S-54S. (Pubitemid 36105786)
73. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002;2:101-12. (Pubitemid 37328797)
74. Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab. 1995;80:2918-25.
75. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem. 2003;278:30458-68. (Pubitemid 36994549)
76. Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast. 2003;12:362-7. (Pubitemid 38008644)
77. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res. 2004;10:331S-6S. (Pubitemid 38116639)
78. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003;95:353-61. (Pubitemid 36395255)
79. Almeida M, Han L, O'Brien C A, Kousteni S, Manolagas SC. Classical genotropic versus kinase-initiated regulation of gene transcription by the estrogen receptor alpha. Endocrinology. 2006;147:1986-96.
80. Manolagas SC, Kousteni S, Chen JR, Schuller M, Plotkin L, Bellido T. Kinase-mediated transcription, activators of nongenotropic estrogen-like signaling (ANGELS), and osteoporosis: a different perspective on the HRT dilemma. Kidney Int Suppl. 2004:S41-9. (Pubitemid 39281714)
81. Kousteni S, Chen JR, Bellido T, et al. Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Science. 2002;298:843-6. (Pubitemid 35231540)
82. Kousteni S, Bellido T, Plotkin LI, et al. Nongenotropic, sexnonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001;104:719-30. (Pubitemid 32241022)
83. Chung YL, Sheu ML, Yang SC, Lin CH, Yen SH. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer. 2002;97:306-12.
84. Razandi M, Alton G, Pedram A, Ghonshani S, Webb P, Levin ER. Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol Cell Biol. 2003;23:1633-46. (Pubitemid 36246045)
85. Johnston SR, Head J, Pancholi S, et al. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res. 2003;9:524S-32S. (Pubitemid 36105797)
86. Johnston SR, Martin LA, Head J, Smith I, Dowsett M. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol. 2005;95:173-81. (Pubitemid 41137308)
87. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, ''pure'' antiestrogen. Cancer. 2000;89:817-25. (Pubitemid 30658581)
88. Howell A, Robertson JF, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22:1605-13. (Pubitemid 41079798)
89. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386-95.
90. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer. 2003;98:229-38. (Pubitemid 36828445)
91. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen- stimulated breast cancer. J Natl Cancer Inst. 2003;95:1597-608. (Pubitemid 37455927)
92. Bulun SE, Lin Z, Imir G, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev. 2005;57:359-83. (Pubitemid 41196955)
93. Simpson ER, Misso M, Hewitt KN, et al. Estrogen-the good, the bad, and the unexpected. Endocr Rev. 2005;26:322-30. (Pubitemid 40686646)
94. Chen S, Itoh T, Wu K, Zhou D, Yang C. Transcriptional regulation of aromatase expression in human breast tissue. J Steroid Biochem Mol Biol. 2002;83:93-9. (Pubitemid 37040645)
95. Clyne CD, Kovacic A, Speed CJ, Zhou J, Pezzi V, Simpson ER. Regulation of aromatase expression by the nuclear receptor LRH-1 in adipose tissue. Mol Cell Endocrinol. 2004;215:39-44. (Pubitemid 38333241)
96. Catalano S, Marsico S, Giordano C, et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem. 2003;278:28668-76. (Pubitemid 36935773)
97. Geisler J, Haynes B, Ekse D, Dowsett M, Lonning PE. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. J Steroid Biochem Mol Biol. 2007;104:27-34. (Pubitemid 46412990)
98. Ray A, Nkhata KJ, Cleary MP. Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol. 2007;30:1499-509.
99. Chen S, Ye J, Kijima I, Kinoshita Y, Zhou D. Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue. J Steroid Biochem Mol Biol. 2005;95:17-23. (Pubitemid 41137289)
100. Yang C, Yu B, Zhou D, Chen S. Regulation of aromatase promoter activity in human breast tissue by nuclear receptors. Oncogene. 2002;21:2854-63. (Pubitemid 34499383)